Prevalence and time of development of systemic arterial hypertension in patients after liver transplantation

Bianca de Oliveira LEMOS¹, Rita de Cássia Martins Alves SILVA²,³, Renato Ferreira da SILVA

ABSTRACT - Background – The use of immunosuppressive drugs after liver transplantation (LT) is associated with the development of systemic arterial hypertension (SAH), in addition to other comorbidities of metabolic syndrome. Objective – Therefore, the purpose of this study was to analyze the time after use immunosuppressive drugs the patient progresses to SAH, as well as to identify its prevalence and the factors that may be correlated to it. Methods – A retrospective and longitudinal study was conducted, based on the analysis of medical records of 72 normotensive patients, attended in the transplant unit of a university hospital, between 2016 and 2019. Results – It was observed, on average, 9±6.98 months after immunosuppressive use, the patients were diagnosed with hypertension, and the prevalence of transplanted patients who evolved to SAH in this study was 59.64% (41 patients). In addition, there was a correlation between serum dosage of tacrolimus and the development of SAH (P=0.0067), which shows that tacrolimus has a significant role in the development of SAH. Finally, it was noticed that the development of post-transplantation hypertension indicates a higher risk of the patient presenting the other parameters of metabolic syndrome, as well as a higher impairment in its renal function (P=0.0061). Conclusion – This study shows that the patients evolved to SAH in an average of 9.26.98 months after immunosuppressive drug use. We have also found high prevalence of systemic arterial hypertension (59.64%) in patients after liver transplantation, who used calcineurin inhibitors, especially when associated with the use of tacrolimus.

INTRODUCTION

The first attempt of liver transplants was performed by Starzl et al. in 1963 in the United States, and in Brazil, this type of transplantation has only occurred for the first time in 1985(1). Initially, however, the survival of patients in the first year was low, only after the discovery of the immunosuppressive drug, cyclosporine, there has been a change in the scenario(2). Currently, the main etiologies of liver diseases that lead to liver transplantation are cirrhosis related to viral hepatitis (HCV, HBV), alcohol, non-alcoholic fatty liver disease and chronic hepatitis C(3). Even with recent advances in surgical techniques and immunosuppression therapies, recent studies(4,5) have shown that patients who have undergone liver transplants tend to have a higher risk of having metabolic syndrome, which include obesity, dyslipidemia, systemic arterial hypertension and hyperglycemia(6).

Systemic arterial hypertension (SAH) manifested after liver transplantation is associated with the use of isolated or associated immunosuppressants, such as calcineurin inhibitors (cyclosporine and tacrolimus), corticosteroids, mTOR (mammalian target of rapamycin inhibitors), in addition to other factors such as alteration of renal function and steatosis(7-9). Calcineurin inhibitors cause widespread arterial vasoconstriction and this promotes sodium re-absorption and, consequently, higher volume of water, which results in increased volemia and this leads to increased blood pressure(10). Thereby, systemic arterial hypertension is a complication in liver transplants recipients and can have severe influences on quality of life and even on morbidity and mortality of individuals(11,12).

This study, therefore, aimed to verify the prevalence of SAH in patients after liver transplantation, in a university hospital, as well as to analyze the factors that could be associated with the presence of hypertension, such as, immunosuppressive drugs and metabolic syndrome.

METHODS

It concerns a retrospective, longitudinal, cohort study based on the analysis of 213 medical records of patients undergoing liver transplantation in a university hospital from 2015 to 2018. The Research Ethics Committee of FAMERP approved the research project.

Were excluded from the research those patients who had previous systemic arterial hypertension or who died within the first five months after transplantation, temporal cutout performed for analysis of the immunosuppressive action. Patients with systolic blood pressure >140 mmHg and/or diastolic blood pressure >90
mmHg and/or in antihypertensive use were considered hypertensive. Of the 213 records checked, 141 were excluded because they had previous SAH or died within the first five months after the transplant. Thus, for this research, were studied 72 patients who underwent liver transplantation and met the inclusion criteria. These patients were divided into two groups: Group A (n=41) which included patients who developed systemic arterial hypertension after transplantation and Group B (n=31) which included patients who did not develop systemic arterial hypertension after transplantation.

Demographic and clinical data were analyzed such as age, gender, Child-Pugh (C-P) classification, Model for End-stage Liver Disease, transplant indication. In addition, the prevalence of systemic arterial hypertension after liver transplantation was verified, as well as the time after transplantation in which SAH developed and the classification according to degree.

Furthermore, body weight variation on the day of admission for the surgery and the body weight 5 months after transplantation were analyzed to verify if there was a statistical difference. The immunosuppressants studied were those prescribed in the first months after transplantation. It was also evaluated the development of diabetes mellitus and the dosage of patients’ creatinine at three different times (1 day after transplant, in addition 3 months and 6 months after transplantation).

The information obtained was inserted into Excel spreadsheet. All statistical analyses were performed with a significance level = 0.05. The Mann-Whitney test was used to compare both groups since the data were not parametric, and Spearman’s Linear Correlation was used for the correlations.

RESULTS

Demographic and clinical data of the patients studied are presented in TABLE 1.

| Variables      | Groups | N  | Mean and SD    | %                           | P value |
|----------------|--------|----|----------------|-----------------------------|---------|
| Age            | A      | 41 | 55.02±10.51    | Male – n= (75.61%)          | 0.3871  |
|                | B      | 31 | 52.03±10.40    | Male – n=23 (74.20%)        |         |
| Gender         | A      | 41 | 60.02±10.51    | A – n=9 (21.95%)            | 0.9185  |
|                | B      | 31 | 52.03±10.40    | B – n=13 (31.70%)           |         |
|                |        |    |                | C – n=19 (46.34%)           |         |
| C-P            | A      | 41 | 23.78±4.43     | MELD > 20 n=28 (68.29%)     | 0.8556  |
|                | B      | 31 | 23.54±4.02     | MELD > 20 n=23 (74.19%)     |         |
| MELD           |        |    |                | Cirrhosis ALD – n=9 (21.95%)|         |
|                |        |    |                | Cirrhosis ALD + HCC + VHC – n=6 (4.63%)|
|                |        |    |                | Cirrhosis ALD + HCC – n=4 (9.75%)|
|                |        |    |                | Cirrhosis ALD + VHC – n=3 (7.31%)|
|                | A      | 41 |                | Cryptogenic cirrhosis – n=3 (7.31%)|
|                |        |    |                | NASH cirrhosis – n=3 (7.31%)|
|                | B      | 31 |                | Cirrhosis ALD + HCC + VBH – n=2 (4.31%)|
|                |        |    |                | Cirrhosis VHC+ HCC – n=2 (4.31%)|
|                |        |    |                | Autoimmune cirrhosis – n=2 (4.31%)|
|                |        |    |                | Fulminant hepatitis – n=2 (4.31%)|
|                |        |    |                | Others – n=5 (12.19%)       |

| Etiologies     |        |    |                | Cirrhosis ALD – n=9 (29.03%)|
|                |        |    |                | Cirrhosis VHC + HCC – n=4 (12.90%)|
|                |        |    |                | Hemochromatosis cirrhosis – N=9 (9.67%)|
|                |        |    |                | Cryptogenic cirrhosis – n=2 (6.45%)|
|                |        |    |                | Cirrhosis AIH + HPS – n=2 (6.45%)|
|                |        |    |                | NASH Cirrhosis – n=2 (6.45%)|
|                |        |    |                | Primary sclerosing cholangitis – n=2 (6.45%)|
|                | B      | 31 |                | Others – n=7 (22.58%)       |

SD: standard deviation; MELD: Model for End-stage Liver Disease; ALD: alcoholic liver disease; HCC: hepatocellular carcinoma; VHC: viral hepatitis cirrhosis; VBH: virus B hepatitis; AIH: autoimmune hepatitis; HPS: hepatopulmonary syndrome; C-P: Child-Pugh.
The presence of systemic arterial hypertension was observed, on average, 9±6.98 months after the use of immunosuppressive drugs, and the prevalence of SAH was 59.64% (41 patients). In addition, there was no statistical difference between the ages of the groups analyzed (P=0.5871), as well as, there were no differences between the other clinical parameters, allowing to observe that the use of immunosuppressive drugs was the predominant factor for the development of comorbidity analysed.

The mean blood pressure measured in patients who developed SAH was systolic blood pressure of 149±10.88 mmHg and diastolic blood pressure of 92±8.82 mmHg. 63.41% (26) of the patients who developed SAH, were already diagnosed in stage I of systemic arterial hypertension, while 36.59% were diagnosed in more advanced stages, as shown in TABLE 2.

TABLE 2. Arterial pressure classification.

| Classification     | %     |
|--------------------|-------|
| Hypertension stage I | 63.41 % (n=26) |
| Hypertension stage II | 29.26 % (n=12) |
| Hypertension stage III | 7.31 % (n=3) |

According to TABLES 3 and 4, it can be verified that there was a statistical difference between the doses of Tacrolimo prescribed when compared to the groups that developed SAH and those that did not develop SAH, as well as, we can observe the correlation between the dosage of Tacrolimo and the development of SAH.

TABLE 3. Difference between groups in relation to the type of immunosuppressive drugs used.

| Medications     | Groups     | Mean ± SD dosage | P value |
|-----------------|------------|------------------|---------|
| Tracolimo       | A – n=35   | 6.65±2.60        | 0.0067  |
|                 | B – n=27   | 4.96±2.18        |         |
| Mycophenolate   | A – n=35   | 871±204          | 0.3022  |
|                 | B – n=29   | 733±289          |         |
| Cyclosporine    | A – n=3    | 258±100          |         |
|                 | B – n=0    | 0                |         |
| Everolimo       | A – n=6    | 2.58±1.23        | 0.4555  |
|                 | B – n=4    | 2±0.70           |         |
| Azathioprine    | A – n=6    | 58.33±18.63      |         |
|                 | B – n=0    | 0                |         |

TABLE 4. Correlation between immunosuppressant dosage and the presence of post-transplant hypertension.

| Medications     | Groups     | P value | R value |
|-----------------|------------|---------|---------|
| Tracolimo       | A – n=35   | 0.0050  | 0.0067  |
|                 | B – n=27   |         |         |
| Mycophenolate   | A – n=35   | 0.2784  | 0.1322  |
|                 | B – n=29   |         |         |
| Cyclosporine    | A – n=3    |         | 0.1322  |
|                 | B – n=0    |         |         |
| Everolimo       | A – n=6    | 0.4711  | 0.2583  |
|                 | B – n=4    |         |         |
| Azathioprine    | A – n=6    |         |         |
|                 | B – n=0    |         |         |

TABLE 5. Comparisons of different variables between groups.

| Variables       | Groups     | Mean and sd | P value |
|-----------------|------------|-------------|---------|
| Body weight variation | A – n=41  | 3.65±9.98   | 0.0459  |
|                 | B – n=31   | -1.61±9.34  |         |
| Diabetes        | A – n=41   |             |         |
|                 | B – n=31   |             |         |
| Creatinine – month 0 | A – n=41  | 1.36±0.9    | 0.4529  |
|                 | B – n=31   | 1.22±0.74   |         |
| Creatinine – month 6 | A – n=41  | 1.325±0.79  | 0.0061  |
|                 | B – n=31   | 1.27±1.45   |         |
| Creatinine – month 12 | A – n=41  | 1.26±0.55   | 0.1085  |
|                 | B – n=31   | 1.22±0.88   |         |

DISCUSSION

Few studies have demonstrated the time when patients were diagnosed with systemic arterial hypertension they only show that the earlier the recognition, prevention and treatment, the better the impact on the patient’s survival. Thus, it was observed in this study that after 9±6.98 months of transplantation and onset of the immunosuppressant, the patients were diagnosed and that 63.41% were in stage I of SAH; 29.26% in stage II and 7.31% in stage III.

In addition, from the data obtained, it is observed that 59.64% of patients acquired systemic arterial hypertension after liver transplantation, a value three times higher than what is expected in the general population, but within the values found in other studies, such as Aparicio LS et al., which observed that the rates of systemic arterial hypertension after liver transplantation were 50–80%.

The development of systemic arterial hypertension in the transplanted patient is associated with the use of immunosuppressive drugs, and many studies relate it to the use of cyclosporine and Tacrolimus, which are calcineurin-inhibiting drugs, since they cause endothelial dysfunction and compromises the vasodilator response, besides producing vasoconstrictor substances and activating the renin angiotensin aldosterone system. Cyclosporine is the immunosuppressive drugs which is most associated with systemic arterial hypertension, when compared to Tacrolimus. According to the article by Canzanello VJ et al., only 33% of patients who used Tacrolimus developed SAH, against those who used cyclosporine, in which 82% of patients became hypertensive. However, we observed that Tacrolimus has a great correlation with systemic arterial hypertension, as 86% of transplanted patients used this drug and among them, 56% evolved to systemic arterial hypertension.
Prevalence and time of development of systemic arterial hypertension in patients after liver transplantation

Lemos BO, Silva RCMA, Silva RF

RESUMO

Arq Gastroenterol. 2021;58(1):77-81.

Lemos BO, Silva RCMA, Silva RF . Prevalência e tempo de desenvolvimento da hipertensão arterial sistêmica em pacientes após transplante de fígado.

Além disso, foi comprovado que o desenvolvimento de hipertensão arterial sistêmica (HAS) após uso de imunossupressores está associado ao desenvolvimento de síndrome metabólica (SM). Esse estudo apresentou um aumento da prevalência de pacientes com HAS e SM após uso de imunossupressores, o que evidencia a importância do monitoramento dessas condições após a transplantação.

CONCLUSÃO

Este estudo mostra que os pacientes evoluíram para HAS em média 9±6.98 meses após o início do uso do imunossupressor. Verificou-se também alta prevalência de hipertensão arterial sistêmica (59,64%) em pacientes pós-transplante de fígado, que usavam inibidores de calcineurina, principalmente, quando associado ao uso de tacrolimus.

DESCRITORES – Transplante de fígado. Hipertensão. Prevalência. Imunossupressores, efeitos adversos. Tacrolimo.
REFERENCES

1. Mies S. Liver Transplantation. Rev. Assoc. Med. Bras., São Paulo, v. 44, n. 2, p. 127-134, June 1998. doi:10.1590/s0104-42301998000200011.

2. Starzl TE, Klintmalm GB, Porter KA, Iwatsuki S, Schroter GP. Liver transplantation with use of cyclosporin-A and prednisone. N Engl J Med. 1981;305:266-9.

3. Chagas AL, Felga GEG, Diniz MA, Silva RF, Matios AA, Silva RCMA, et al. Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival. Eur J Gastroenterol Hepatol. 2019;31:1148-56. doi: 10.1097/MEG.0000000000001448.

4. Watt KDS, Chariton MR. Metabolic syndrome and liver transplantation: A review and guide to management. J Hepatol. 2010;53:199-206. doi: 10.1016/j.jhep.2010.01.040.

5. Zheng J, Wang WL. Risk factors of metabolic syndrome after liver transplantation. Hepatobiliary Pancreat Dis Int. 2015;14:582-7. doi: 10.1016/s1499-3872(15)60037-6.

6. Pérez MJ, Grande RG, Gusmán EO, Trillo VA, López JMR. Metabolic complications in liver transplant recipients. World J Gastroenterol. 2016;22:6416-23. doi: 10.3748/wjg.v22.i28.6416.

7. Di Stefano C, Vanni E, Mirabella S, Younes R, Boano V, Mosso E. Risk factors for arterial hypertension after liver transplantation. J Am Soc Hypertens. 2018;12:220-9. doi: 10.1016/j.jash.2018.01.002.

8. Luiz FK, Melo GC, Alves GA, Pinto GS, Vilela AM, Younes R, et al. Arterial hypertension in liver transplant recipients. Rev Esp Enferm Dig. 2017;109:15-20. doi: 10.1016/j.reden.2016.12.016.

9. Passos VMA, Assis TD, Barreto SM. Arterial hypertension in Brazil: prevalence estimate from population-based studies. Epidemiol Serv Saúde, Brasília. 2006;15(1):35-45. doi: 10.5123/S1679-49742006000100003.

10. Lobo LAC, Canuto R, Dias da Costa JS, Pattussi MT. [Temporal trend in the prevalence of systemic arterial hypertension in Brazil]. [Article in Portuguese]. Cad. Saúde Pública. 2017;33:e00035316. doi:10.1590/0102-311X00035316.

11. Aparicio L, Allie J, Barochiner J, Cuffaro P, Rada M, Morales M, Galarza C, Waisman G. Hypertension: The Neglected Complication of Transplantation. ISRN Hypertension. 2013. doi: 10.5402/2013/16937.

12. Friedrich C, Luft, How calcineurin inhibitors cause hypertension, Nephrology Dialysis Transplantation. 2012;27:473-5. doi: 10.1093/ndt/gfr679.

13. Textor SC, Taler SJ, Canzanello VJ, Schwartz L, Augustine JE. Posttransplantation Hypertension Related to Calcineurin Inhibitors Liver Transpl. 2000;6:521-30.

14. Canzanello VJ, Schwellenbach EH, Schwartz L, Augustin JE,TEXTOR SC, Taler SJ. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). Liver Transpl. 1998;4:328-34.

15. Gojowy D, Adamczak M, Dudzicz S, Gazda M, Karkoszka H, Wiecek A, High Frequency of arterial hypertension in patients after liver transplantation. Transplant Proc. 2016;48:1721-4. doi: 10.1016/j.transproceed.2015.11.043.

16. Laish I, Braun M, Eross Z, Zeyneloglu P, Pirat A, Torgay Adnam, Hanerel M. Incidence of acute kidney injury following liver transplantation. Transplantation;2018;102:S855. doi 10.1097/01.tp.0000543927.74859.54

17. Canzanello VJ, Schwartz L, Taler SJ, Textor SC, Wiesner RH, Krom RA. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg. 1997;3:1-9.

18. Canzanello VJ, Schwartz L, Taler SJ, Textor SC, Wiesner RH, Krom RA. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). Liver Transpl. 1998;4:328-34.

19. Textor SC, Taler SJ, Schwartz L, Augustine JE. Posttransplantation Hypertension Related to Calcineurin Inhibitors Liver Transpl. 2000;6:521-30.

20. Canzanello VJ, Textor SC, Taler SJ, Schwartz LL, Porayko MK, Wiesner RH, Krom RA. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). Liver Transpl. 1998;4:328-34.